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A B S T R A C T
Purpose
Racial disparities in cancer treatment and outcomes are a national problem. The nationwide
Veterans Affairs (VA) health system seeks to provide equal access to quality care. However, the
relationship between race and care quality for veterans with colorectal cancer (CRC) treated within
the VA is poorly understood. We examined the association between race and receipt of National
Comprehensive Cancer Network guideline–concordant CRC care.
Patients and Methods
This was an observational, retrospective medical record abstraction of patients with CRC treated
in the VA. Two thousand twenty-two patients (white, n  1,712; African American, n  310)
diagnosed with incident CRC between October 1, 2003, and March 31, 2006, from 128 VA medical
centers, were included. We used multivariable logistic regression to examine associations
between race and receipt of guideline-concordant care (computed tomography scan, preoperative
carcinoembryonic antigen, clear surgical margins, medical oncology referral for stages II and III,
fluorouracil-based adjuvant chemotherapy for stage III, and surveillance colonoscopy for stages I
to III). Explanatory variables included demographic and disease characteristics.
Results
There were no significant racial differences for receipt of guideline-concordant CRC care. Older
age at diagnosis was associated with reduced odds of medical oncology referral and surveillance
colonoscopy. Presence of cardiovascular comorbid conditions was associated with reduced odds
of medical oncology referral (odds ratio, 0.65; 95% CI, 0.50 to 0.89).
Conclusion
In these data, we observed no evidence of racial disparities in CRC care quality. Future studies
could examine causal pathways for the VA’s equal, quality care and ways to translate the VA’s
success into other hospital systems.
J Clin Oncol 31:3579-3584. © 2013 by American Society of Clinical Oncology
INTRODUCTION
The Veterans Affairs (VA) health care system is the
largest provider of integrated cancer care in the
United States, treating approximately 3% of newly
diagnosed patients with cancer nationwide.1 Among
VA patients, colorectal cancer (CRC) is a common
disease.1 In fact, CRC is the third most commonly
diagnosed cancer and third most common cause of
cancer-related death nationwide.2 In nonfederal US
health care systems, racial differences in CRC
diagnosis, treatment, and mortality have been
documented.3-13 For example, fewer African Amer-
icans receive adjuvant chemotherapy for CRC com-
pared with whites.5,7,14 Compared with white
patients, cancer surveillance is lower and cancer-
related mortality is higher among African American
patients.5,9,10 Unequal access to health care services
has been attributed as a contributing factor for racial
disparities in care.3,15,16 The VA health care system
provides a good context in which to study racial
disparities because of standard VA eligibility criteria
and narrow distribution of family income among
VA patients, making access issues among individu-
als of different races narrower than for non-VA sys-
tems.17 Although racial health care disparities have
been noted for some conditions, the degree of racial
disparities identified in the quality of VA health care
is often less than what is found in other health
care systems.18,19
There is paucity of information regarding racial
disparities in VA CRC care quality for patients of
diverse race. Previous studies suggest that racial dif-
ferences in CRC treatment may be diminished in the
VA.16,20,21 However, these studies were based on
a limited number of quality measures that can
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be evaluated based solely on administrative data. We extend previous
research by including additional data sources (ie, a comprehensive
review of electronic health record data, supplemented with adminis-




Data were from the External Peer Review Program (EPRP), the national
program for tracking quality of VA health care.22 Between July and August
2007, medical record abstraction was conducted under the guidance of the VA
Office of Quality and Performance to assess CRC care quality. Abstractors
accessed the electronic medical record (EMR) remotely, collecting data on
disease characteristics and health care delivery provided to individuals across
the VA nationwide. We supplemented EPRP with clinical comorbidity and
demographic information from the VA Central Cancer Registry (VACCR)
and administrative data. The institutional review boards at the Durham VA
Medical Center and at the University of North Carolina at Chapel Hill ap-
proved this project.
Patient Sample
The sample has previously been described in detail.23 Briefly, patients
were identified for EPRP inclusion based on a search algorithm defining a
representative sample of VA patients diagnosed with CRC between October 1,
2003, and March 31, 2006, using administrative diagnosis, procedure, and
encounter data.23,24 Eligible patients had an International Classification of
Diseases code for colon and/or rectal cancer within 3 months of the study
diagnosis time period.23,25 Eligible patients must have had a clinic visit, surgical
procedure, or pathology report in the VA that corresponded with a specific
visit or receipt of medical services within the aforementioned time frame. To
be in the final analytic data set, patients also must have had nonmetastatic CRC
(stages I to III), had an incident occurrence (first diagnosis of CRC occurred
during the study time period), and received definitive CRC surgical resection.
Because their recommended patterns of health care and life expectancy are
different than patients with earlier stage disease, those with metastatic disease
(stage IV) were excluded. Furthermore, to be included in this analysis, patients
must have successfully linked with the VA administrative data sources. In
other words, patients must have had matching records in both the EPRP
quality tracking data source as well as the VA administrative data. The admin-
istrative data are generated when a patient interacts with the VA health care
system, either in an inpatient or outpatient setting, to receive health care.
Because of the small number of non–African American minorities and
women, we restricted the study to white and African American male patients
(Fig 1).
Dependent Variables
We used six distinct CRC quality indicators based on 2003 National
Comprehensive Cancer Network guidelines26,27 that have scientific evidence
and/or National Comprehensive Cancer Network panel consensus.23,26,27
Each indicator applied to a subset of patients as determined by stage and other
factors. The specific quality indicators, by stage, were as follows. For stages II
and III CRC, the quality indicators were preoperative computed tomography
(CT) scan of the abdomen and pelvis before definitive surgical resection;
preoperative carcinoembryonic antigen determination before definitive surgi-
cal resection; documented radial margins free of tumor at the time of definitive
surgical resection; and referral to a medical oncologist. Because our intent was
to evaluate equity in access to quality care, patients with documentation of a
refusal (eg, refused CT scan) in the EMR were included in the quality indicator
as having received guideline-concordant care. For stage III CRC, the quality
indicator was receipt of adjuvant fluorouracil- (FU) or capecitabine-based
chemotherapy administered after definitive surgical resection. If the EMR
contained a documented reason why FU was not administered, that was
included in the quality indicator calculation as having received guideline-
concordant care. For patients with stage I to III CRC who did not have
documentation of an obstructing preoperative lesion, the quality indicator was
receipt of surveillance colonoscopy within 7 to 18 months after definitive
surgical resection. Consistent with previous analyses,23 7 months was used
as a minimum because colonoscopies performed earlier might not be
intended for surveillance, and 18 months was chosen because surveillance
colonoscopies may not occur exactly within 1 year. To be included in the
surveillance colonoscopy measure, patients must have survived at least 1
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Fig 1. Colorectal cancer cohort assembly. EPRP, External Peer
Review Program.
Table 1. Key Variables
Variable No. of Patients/Total No. %
Dependent variables
CT scan 1,022/1,410 72.48
Preoperative CEA 1,175/1,410 83.33
Clear surgical margins 1,155/1,393 82.91
Referral to a medical oncologist 1,103/1,410 78.23
Adjuvant FU chemotherapy 487/653 74.58
Surveillance colonoscopy 869/2,006 43.32
Independent variable
White race 1,712/2,022 84.67
Other control variables
Age at diagnosis, years















Liver disease 11/2,022 0.54
Rheumatoid disease or AIDS 23/2,022 1.14
Renal disease 53/2,022 2.62
Dementia or paralysis 5/2,022 0.25
CHF, acute MI, CVD, or
COPD 485/2,022 23.99
Diabetes 541/2,022 26.76
Abbreviations: CEA, carcinoembryonic antigen; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; CT, computed tomography;
CVD, cardiovascular disease; FU, fluorouracil; MI, myocardial infarction.
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Independent Variables
The primary independent variable of interest was race. We used a hier-
archy of sources to determine the most accurate race measure. Because data
were obtained through EMR review by trained cancer registrars, the VACCR
was considered the most valid source. If race was not reported in the VACCR,
then race was extracted from the inpatient medical record, followed by outpa-
tient medical record information.
Other covariates included marital status (married or not), age at diagno-
sis ( 55, 55 to 64, 65 to 74, or  75 years), geographic region (west, south,
east, or central), comorbid conditions, and, when applicable, stage of disease
(I, II, or III). The included comorbid conditions were based on the National
Cancer Institute Combined Comorbidity Index, which has been validated in
patients with CRC.28 We identified diagnoses for comorbid conditions with
International Classification of Diseases codes from medical inpatient and
outpatient administrative data files.25 To be included, comorbid conditions
must have been diagnosed within the year before the CRC diagnosis, excluding
those comorbidities occurring in the 30 days leading up to diagnosis. This is
because the 30 days before a cancer diagnosis often involve multiple interac-
tions with the health care system, and patients may be diagnosed, sometimes
erroneously, with comorbidities that are actually cancer symptoms or se-
quelae. To ensure that analyses had adequate statistical power to address the
study question, we aggregated conditions based on consultation with a medi-
cal oncologist and statistical examination to ensure no valuable information
was lost (eg, collapsing a positively correlated condition with a negatively
correlated condition).29 Individual comorbid conditions included the follow-
ing: liver disease; rheumatoid disease/AIDS; renal disease; dementia/paralysis;
congestive heart failure, acute myocardial infarction, cardiovascular disease, or
chronic obstructive pulmonary disease; and diabetes. This approach enabled
examination of the effect of specific conditions on receipt of guideline-
concordant care, an advantage over an aggregate comorbidity score.
Data Analysis
Multivariable logistic regression was used to determine the association
between race and receipt of guideline-concordant CRC care. Pearson’s 2 tests
were used to determine whether there were significant differences between
groups for background demographic and clinical characteristics. Because this
analysis examines multiple comparisons (eg, race, age at diagnosis), we used
the Bonferroni adjustment to control for family-wise error. Therefore, associ-
ations between independent variables and quality indicators were considered
statistically significant if P  .01. Stata 11 (StataCorp LP, College Station, TX)
and SAS version 9.2 (SAS Institute, Cary, NC) were used for data management
and analyses.
RESULTS
The final sample consisted of 2,022 men with incident CRC (Fig 1).
The mean age at diagnosis was 68 years (range, 34 to 94 years).
Reflecting the overall VA patient population, the sample was pre-
dominately white (85%) and married (52%) and lived in the south
(38%). Stage was approximately evenly distributed. The most
commonly diagnosed comorbid conditions were diabetes (27%)
and cardiovascular-related diseases (24%; Table 1).
There were no significant racial differences in receipt of quality
CRC care in the VA (Tables 2 and 3). In these data, race was not
associated with receipt of guideline-concordant care for the examined
quality indicators.
Compared with patients age 75 years or older at diagnosis, pa-
tients age 55 to 64 years at diagnosis had marginally greater odds of










OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P
Demographic
White 1.22 0.88 to 1.70 .23 1.17 0.80 to 1.72 .41 0.71 0.43 to 1.19 .19 1.46 1.00 to 2.13 .05
Married 0.82 0.64 to 1.04 .11 1.13 0.84 to 1.50 .42 1.02 0.73 to 1.44 .90 0.85 0.64 to 1.11 .23
Age at diagnosis, years
 55 1.03 0.67 to 1.58 .88 1.04 0.62 to 1.80 .87 0.70 0.39 to 1.25 .23 2.45 1.42 to 4.23  .01
55-64 1.51 1.11 to 2.05 .01 1.33 0.91 to 1.93 .14 0.90 0.58 to 1.38 .62 1.89 1.34 to 2.65  .01
65-74 1.20 0.59 to 1.63 .24 0.87 0.61 to 1.24 .44 1.00 0.63 to 1.60 1.00 1.66 1.18 to 2.35  .01
75 (referent)
Region
North 1.71 1.20 to 2.43  .01 1.32 0.88 to 1.98 .18 2.25 1.22 to 4.14 .01 3.22 1.96 to 5.30  .01
Central 1.91 1.37 to 2.67  .01 0.98 0.69 to 1.41 .93 0.93 0.60 to 1.43 .73 1.25 0.86 to 1.82 .23
West 1.21 0.88 to 1.66 .24 2.88 1.79 to 4.64  .01 0.85 0.55 to 1.31 .46 0.42 0.30 to 0.58  .01
South (referent)
Comorbidity
Liver disease 1.15 0.23 to 5.82 .86 0.37 0.08 to 1.61 .18 0.47 0.09 to 2.48 .38 0.78 0.14 to 4.34 .78
Rheumatoid disease or AIDS 0.99 0.34 to 2.91 .99 0.63 0.20 to 1.99 .43 —† 1.53 0.42 to 5.59 .52
Renal disease 0.60 0.30 to 1.24 .17 3.43 0.80 to 14.65 .10 1.80 0.41 to 7.85 .43 1.08 0.46 to 2.54 .85
Dementia or paralysis 0.67 0.11 to 4.20 .67 0.13 0.02 to 0.83 .03 0.18 0.03 to 1.15 .07 1.27 0.13 to 12.15 .84
CHF, acute MI, CVD, or COPD 0.82 0.63 to 1.09 .19 0.96 0.69 to 1.35 .82 0.86 0.58 to 1.29 .47 0.65 0.50 to 0.89 .01
Diabetes 0.93 0.71 to 1.23 .62 1.03 0.73 to 1.43 .88 1.20 0.80 to 1.80 .38 1.02 0.74 to 1.40 .90
Stage at diagnosis
III 1.06 0.83 to 1.35 .63 1.04 0.78 to 1.38 .81 0.44 0.31 to 0.62  .01 2.70 2.03 to 3.60  .01
II (referent)
Abbreviations: CEA, carcinoembryonic antigen; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CRC, colorectal cancer; CT, computed
tomography; CVD, cardiovascular disease; MI, myocardial infarction; OR, odds ratio.
Indicates statistical significance of P  .01.
†Because of perfect prediction between rheumatoid disease and AIDS, 17 observations were excluded.
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having a preoperative CT scan (odds ratio [OR], 1.51; 95% CI, 1.11 to
2.05). Similarly, compared with patients age 75 years or older, younger
patients had greater odds of a medical oncology referral (age  55
years: OR, 2.45; 95% CI, 1.42 to 4.23; age 55 to 64 years: OR, 1.89; 95%
CI, 1.34 to 2.65; age 65 to 74 years: OR, 1.66; 95% CI, 1.18 to 2.35;
Table 2). Patients who were age 65 to 74 years old had greater odds of
receiving surveillance colonoscopy than patients who were age 75
years or older (OR, 1.47; 95% CI, 1.14 to 1.89; Table 3).
For the majority of quality indicators, there was no association
between individual comorbid conditions and receipt of guideline-
concordant care. Patients with cardiovascular-related comorbidities
had lower odds of referral to a medical oncologist (OR, 0.65; 95% CI,
0.50 to 0.89) than patients without cardiovascular conditions
(Table 2).
Limited associations between stage and receipt of guideline-
concordant care may reflect disease severity. Patients with stage III
disease had lower odds of clear surgical margins (OR, 0.44; 95% CI,
0.31 to 0.62) than those with stage II disease (Table 2). Patients with
stage III disease had increased odds of referral to medical oncology
(OR, 2.70; 95% CI, 2.03 to 3.60). Odds of receiving surveillance
colonoscopy were lower among patients with stage I disease (OR, 0.71;
95% CI, 0.56 to 0.90) compared with patients with stage II disease
(Table 3).
Bivariate analyses indicated that patient refusals and/or physician
documentation of a clinical contraindication for therapy were not
masking racial disparities in care. One white patient refused preoper-
ative CT scan. The association between race and CT refusal was not
statistically significant (P  .36). Regarding receipt of adjuvant FU-
based chemotherapy for patients with stage III disease, 11 patients
(one African American and 10 white patients) refused treatment and
32 patients (five African American and 27 white patients) had physi-
cian documentation of a clinical contraindication precluding receipt
of chemotherapy. This represented 3% of the sample for the FU-based
chemotherapy measure (43 of 1,410 patients), and the association
with race was not significant (P  .37).
DISCUSSION
Historically, the VA was criticized for its overall organization and
management and providing poor care quality.30,31 In 1995, the VA
began a system-wide transformational redesign with emphasis on
using information technology, reporting quality performance, and
integrating medical services.32-35 Recent reports suggest that the VA is
now a leader in information technology and delivery of high-quality
care.23,35-37 The question that we address is whether this overall quality
transformation has also reduced racial disparities in guideline-
concordant CRC care.
We found a lack of evidence of racial disparities in receipt of
guideline-concordant CRC care. This contrasts with prior studies in
Table 3. Multivariate Logistic Regression Results for Receipt of Adjuvant FU-Based Chemotherapy and Surveillance Colonoscopy
Variable
Adjuvant FU Chemotherapy (n  653) Surveillance Colonoscopy (n  2006)
OR 95% CI P OR 95% CI P
Demographic
White 1.23 0.77 to 1.97 .40 1.32 1.01 to 1.73 .04
Married 1.30 0.90 to 1.88 .16 1.00 0.82 to 1.22 1.00
Age at diagnosis, years
 55 1.70 0.86 to 3.38 .13 1.12 0.77 to 1.62 .55
55-64 1.03 0.65 to 1.62 .91 1.20 0.93 to 1.53 .16
65-74 1.15 0.71 to 1.87 .57 1.47 1.14 to 1.89 .01†
75 (referent)
Region
North 1.75 1.00 to 3.07 .05 1.28 0.96 to 1.71 .09
Central 1.52 0.95 to 2.42 .08 0.84 0.65 to 1.08 .18
West 1.30 0.79 to 2.14 .31 1.01 0.77 to 1.33 .93
South (referent)
Comorbidity
Liver disease 0.28 0.04 to 2.11 .22 —‡
Rheumatoid disease or AIDS 1.11 0.20 to 6.17 .90 1.00 0.40 to 2.46 .99
Renal disease 0.68 0.22 to 2.14 .51 0.87 0.49 to 1.56 .65
Dementia or paralysis 0.17 0.01 to 2.03 .16 —§
CHF, acute MI, CVD, or COPD 0.82 0.53 to 1.25 .35 0.84 0.67 to 1.06 .14
Diabetes 0.84 0.56 to 1.26 .40 0.86 0.69 to 1.08 .20
Stage at diagnosis
I 0.71 0.56 to 0.90  .01†
II (referent)
III 0.97 0.77 to 1.24 .83
Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; FU, fluorouracil; MI, myocardial infarction;
OR, odds ratio.
Stage is not included because only patients with stage III colorectal cancer were included per National Comprehensive Cancer Network guidelines.
†Indicates statistical significance of P  .01.
‡Because of issues of perfect prediction with liver disease, 11 observations were excluded.
§Because of perfect prediction with dementia/paralysis, five observations were excluded.
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nonfederal hospitals that observed racial differences in receipt of CRC
care, for example, in receipt of screening colonoscopies.3,38,39 How-
ever, there is a dearth of information about racial differences in sur-
veillance colonoscopy receipt after surgery. We identified no racial
differences for surveillance colonoscopy.
Colonoscopy is not without risks; differences in receipt of surveil-
lance colonoscopy based on stage and age at diagnosis may be appro-
priate. There is evidence that intensive postsurgery surveillance can
increase survival,40-42 but a direct clinical benefit for surveillance
colonoscopy alone has not been established. Despite this, clinical
guidelines assert that surveillance colonoscopy is an important com-
ponent of guideline-concordant CRC surveillance.26,27,43
Studies from the Surveillance, Epidemiology, and End Results–
Medicare registry found differences in oncologist evaluation
rates between white and African American patients, but the gap
decreased substantially over time. Contingent on consulting
with a medical oncologist, there were no racial differences in treat-
ment receipt.44 However, there are differences based on age at
diagnosis. Clinical trials generally do not enroll elderly people; the
clinical benefit of adjuvant chemotherapy on older people has not
been tested extensively in a trial setting, and older patients often do
not receive FU-based chemotherapy in the private health care
setting.45 Regarding race, there is evidence that the clinical benefit
of FU may be lower for African American patients than for
white patients.14,46
In our analysis, age and stage at diagnosis were associated with
medical oncology referral. The difference in stage, where patients
with stage III disease have greater odds of referral than patients
with stage II disease, is likely clinically appropriate. Our study
sample was diagnosed in 2003 to 2006. At the time these patients
received treatment, chemotherapy for patients with stage II disease
was controversial. This association may reflect clinicians’ knowl-
edge of clinical practice guidelines. However, differences in referral
patterns based on stage, age, and cancer type require further examina-
tion. We found no association between race and medical oncology
referral. Medical oncology referral typically precedes chemotherapy.
In this VA population, we also found no association between race or
age and FU-based chemotherapy receipt.
We found differences in receipt of care based on the presence of
specific comorbid conditions—patients with cardiovascular condi-
tions were less likely to be referred to a medical oncologist. This may be
a result of contraindications for chemotherapy. Clinical appropriate-
ness of referral was not addressed in our analysis.
There are several limitations to this study. First, we were
unable to control for potentially confounding sociodemo-
graphic status, which may mediate associations between race
and care quality. This potential omission bias is likely mitigated
because VA patients receive care on a sliding fee scale based on
ability to pay and by service-connected status.47 Nearly one half
of VA patients have family incomes of less than $20,000.17
Second, we did not have information regarding Hispanic eth-
nicity. Third, data were abstracted from the VA EMR and
administrative data; we lacked data on care received outside of
the VA health care system or care not documented in the
available data sources. We could not address possible reasons
for the VA’s lack of disparities. The VA strives to be an equal-
access system, which may be one reason for the success in this
area. Other reports have hypothesized that this is a potential
reason for reduced levels of health care disparities in the
VA.21,48,49 Generalizability of findings has been questioned in
studies of VA populations; however, it is notable that our sam-
ple population is of similar age (eg, 68 years in our sample, 69
years nationally) and stage distribution to that of the US popu-
lation of male patients with colon cancer. Additionally, we
examined the data for specific situations, such as patients’ re-
fusal of care or physicians’ documentation of clinical contrain-
dications precluding care, that might impact our findings and
mask potential racial disparities. Although these data suggest
that this is not an issue, it remains possible that there may be
unmeasured racial discrimination.50,51
In summary, we observed no evidence of racial disparities in
receipt of quality CRC care provided by the VA health care system.
As other clinical programs within the VA seek to strengthen their
approach to quality management, they may evaluate the lessons
that can be learned from successful CRC programs and specific
changes such as electronic reminder systems, multidisciplinary
collaborative improvement groups, and electronic tools for quality
monitoring. Given that the VA treats 3% of newly diagnosed
patients with cancer annually,1 it is plausible that the benefit of
widespread quality improvement within the VA would influence
the landscape of cancer care and outcomes nationally. Other health
care systems could also consider aspects of VA care that could be
translatable to reduce racial disparities in cancer care. Future stud-
ies with larger sample sizes are needed to examine causal pathways
for the VA’s equal, quality care and ways to translate the VA’s
success into other hospital systems.
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